Literature DB >> 26001564

High-Throughput Silencing Using the CRISPR-Cas9 System: A Review of the Benefits and Challenges.

Mark Wade1.   

Abstract

The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system has been seized upon with a fervor enjoyed previously by small interfering RNA (siRNA) and short hairpin RNA (shRNA) technologies and has enormous potential for high-throughput functional genomics studies. The decision to use this approach must be balanced with respect to adoption of existing platforms versus awaiting the development of more "mature" next-generation systems. Here, experience from siRNA and shRNA screening plays an important role, as issues such as targeting efficiency, pooling strategies, and off-target effects with those technologies are already framing debates in the CRISPR field. CRISPR/Cas can be exploited not only to knockout genes but also to up- or down-regulate gene transcription-in some cases in a multiplex fashion. This provides a powerful tool for studying the interaction among multiple signaling cascades in the same genetic background. Furthermore, the documented success of CRISPR/Cas-mediated gene correction (or the corollary, introduction of disease-specific mutations) provides proof of concept for the rapid generation of isogenic cell lines for high-throughput screening. In this review, the advantages and limitations of CRISPR/Cas are discussed and current and future applications are highlighted. It is envisaged that complementarities between CRISPR, siRNA, and shRNA will ensure that all three technologies remain critical to the success of future functional genomics projects.
© 2015 Society for Laboratory Automation and Screening.

Keywords:  CRISPR; Cas9; genomics; screen; siRNA

Mesh:

Substances:

Year:  2015        PMID: 26001564     DOI: 10.1177/1087057115587916

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  16 in total

Review 1.  Genetic studies in intellectual disability and related disorders.

Authors:  Lisenka E L M Vissers; Christian Gilissen; Joris A Veltman
Journal:  Nat Rev Genet       Date:  2015-10-27       Impact factor: 53.242

2.  Scalpel or Straitjacket: CRISPR/Cas9 Approaches for Muscular Dystrophies.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Trends Pharmacol Sci       Date:  2016-02-22       Impact factor: 14.819

Review 3.  High-Throughput Imaging for the Discovery of Cellular Mechanisms of Disease.

Authors:  Gianluca Pegoraro; Tom Misteli
Journal:  Trends Genet       Date:  2017-07-18       Impact factor: 11.639

Review 4.  Cell-Based Assay Design for High-Content Screening of Drug Candidates.

Authors:  Gregory Nierode; Paul S Kwon; Jonathan S Dordick; Seok-Joon Kwon
Journal:  J Microbiol Biotechnol       Date:  2016-02       Impact factor: 2.351

Review 5.  Overview of the Muscle Cytoskeleton.

Authors:  Christine A Henderson; Christopher G Gomez; Stefanie M Novak; Lei Mi-Mi; Carol C Gregorio
Journal:  Compr Physiol       Date:  2017-06-18       Impact factor: 9.090

6.  Metabolic engineering of Escherichia coli for efficient production of L-arginine.

Authors:  Hai-De Wang; Jian-Zhong Xu; Wei-Guo Zhang
Journal:  Appl Microbiol Biotechnol       Date:  2022-08-06       Impact factor: 5.560

Review 7.  T-cell therapies for HIV: Preclinical successes and current clinical strategies.

Authors:  Shabnum Patel; R Brad Jones; Douglas F Nixon; Catherine M Bollard
Journal:  Cytotherapy       Date:  2016-06-02       Impact factor: 5.414

8.  Dynamic Heterogeneity of Brachyury in Mouse Epiblast Stem Cells Mediates Distinct Response to Extrinsic Bone Morphogenetic Protein (BMP) Signaling.

Authors:  Lu Song; Jun Chen; Guangdun Peng; Ke Tang; Naihe Jing
Journal:  J Biol Chem       Date:  2016-05-16       Impact factor: 5.157

Review 9.  The ABCC6 Transporter as a Paradigm for Networking from an Orphan Disease to Complex Disorders.

Authors:  Eva Y G De Vilder; Mohammad Jakir Hosen; Olivier M Vanakker
Journal:  Biomed Res Int       Date:  2015-08-18       Impact factor: 3.411

Review 10.  Weaknesses and Pitfalls of Using Mice and Rats in Cancer Chemoprevention Studies.

Authors:  Yukui Ma; Yuping Jia; Lichan Chen; Lewis Ezeogu; Baofa Yu; Ningzhi Xu; D Joshua Liao
Journal:  J Cancer       Date:  2015-09-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.